Statin-induced myotoxicity: Pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular Reference to pitavastatin

Current Vascular Pharmacology

Volumn 10, Issue 2, 2012, Pages 257-267

  Catapano, Alberico L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Atorvastatin; Drug drug interactions; Kidney failure; Lovastatin; Myotoxicity; Pitavastatin; Pravastatin; Rhabdomyolysis; Rosuvastatin; Simvastatin; Statin

Indexed keywords

ANTIFUNGAL AGENT; ATAZANAVIR; ATORVASTATIN; BEZAFIBRATE; BREAST CANCER RESISTANCE PROTEIN; CERIVASTATIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DIGOXIN; ENALAPRIL; ERYTHROMYCIN; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MACROLIDE; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 1; PITAVASTATIN; PRAVASTATIN; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CREATINE KINASE BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG SAFETY; DRUG UPTAKE; DRUG WITHDRAWAL; DYSLIPIDEMIA; GRIP STRENGTH; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; LIVER CELL; MALAISE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUSCLE CRAMP; MUSCLE DISEASE; MUSCLE SPASM; MUSCLE STIFFNESS; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; NECK PAIN; PHARMACOGENOMICS; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; QUINOLINES; RHABDOMYOLYSIS; RISK;

EID: 84857127538     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112799305021     Document Type: Article

References (58)

1. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006; 97: 69C-76C.
2. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2: 205-7.
3. Mastaglia FL. Iatrogenic myopathies. Curr Opin Neurol 2010; 23: 445-9.
4. Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567-72.
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
6. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006; 97: 61C-8C.
7. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52C-60C.
8. Baker WL, Datta R. Pitavastatin: a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia. Adv Ther 2011; 28: 13-27.
9. Catapano AL. Pitavastatin - pharmacological profile from early phase studies. Atheroscler Suppl 2010; 11: 3-7.
10. da Silva PM. Are all statins the same?: focus on the efficacy and tolerability of pitavastatin. Am J Cardiovasc Drugs 2011; 11: 93-107.
11. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-90.
12. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
13. Kasliwal R, Wilton LV, Cornelius V, Aurich-Barrera B, Shakir SA. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients. Drug Saf 2007; 30: 157-70.
14. Maruyama T, Takada M, Nishibori Y, et al. Comparison of preventive effect on cardiovascular events with different statins. Circ J 2011; 75: 1951-9.
15. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006; 34: 1229-36.
16. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25: 649-63.
17. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-90.
18. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004; 13: 417-26.
19. Davidson MH. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf 2004; 3: 547-57.
20. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403-14.
21. Silva M, Matthews ML, Jarvis C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007; 29: 253-60.
22. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006; 97: 27C-31C.
23. Corsini A, Bellosta S. Drug-drug interaction with statins. Exp Rev Clin Pharmacol 2008; 1: 105-13.
24. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008; 47: 463-74.
25. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112: 71-105.
26. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-95.
27. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-17.
28. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. Jama 2003; 289: 1681-90.
29. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin vs. gemfibrozil + any statin. Am J Cardiol 2005; 95: 120-2.
30. Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol 2009; 5: 507-18.
31. Sacks FM. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Am J Cardiol 2008; 102: 34L-40L.
32. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-61.
33. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-74.
34. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-92.
35. Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs. statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin 2011; 27: 1191-210.
36. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009-26.
37. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-81.
38. Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? CMRO [Review] 2011; 27: 1551-62.
39. Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 2004; 34: 961-71.
40. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78: 260-77.
41. Skottheim IB, Gedde-Dahl A, Hejazifar S, Hoel K, Asberg A. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci 2008; 33: 317-25.
42. Hermann M, Bogsrud MP, Molden E, et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 2006; 79: 532-9.
43. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008; 359: 789-99.
44. Furihata T, Satoh N, Ohishi T, et al. Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy. Pharmacogenomics J 2009; 9: 185-93.
45. Bailey KM, Romaine SP, Jackson BM, et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ Cardiovasc Genet 2010; 3: 276-85.
46. Tomlinson B, Hu M, Lee VW, et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther 2010; 87: 558-62.
47. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008; 84: 457-61.
48. Keskitalo JE, Kurkinen KJ, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol 2009; 68: 207-13.
49. Ieiri I, Suwannakul S, Maeda K, et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2007; 82: 541-7.
50. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8: 787-802.
51. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004; 311: 228-36.
52. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004; 311: 139-46.
53. Hounslow N. Pitavastatin has a low risk of drug-drug interactions: pharmacokinetic studies in combination with modulators of CYP450 and OATP. Presented at XVII International Symposium on Drugs Affecting Lipid Metabolism. Diabetes, Obesity, and the Metabolic Syndrome. Doha, Qatar, March 14-16, 2011.
54. Kobayashi M, Chisaki I, Narumi K, et al. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. Life Sci 2008; 82: 969-75.
55. Kurihara Y, Douzono T, Kawakita K, Fujita S, Nachi S, Nagasaka Y. A large-scale, prospective post-marketing surveillance of pitavastatin (LIVALOTM Tablet) - Drug use investigation. Jpn Pharmacol Ther 2007; 35: 9-40.
56. Ose L, Budinski D, Hounslow N, Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010; 210: 202-8.
57. Wiviott SD, Cannon CP. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol 2006; 17: 626-30.
58. Kurihara Y, Douzono T, Kawakita K, Nagasaki Y. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO Tablet): LIVALO Effectiveness and Safety (LIVES) study. Jpn Pharmacol Ther 2008; 36: 709-31.